What's Going On With Tempus AI Stock Today?

Tempus AI (NASDAQ:TEM) rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors.

The next-generation model analyzes gene expression to help identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, offering what the company says is a more dynamic assessment of tumor biology than traditional genomic methods. In a real-world validation study, HRD-RNA–positive metastatic pancreatic cancer patients treated with first-line platinum-based regimens saw a significant reduction in mortality risk compared with those receiving non-platinum therapies.

Tempus plans to make the test clinically available later this year. Chief Development Officer Halla Nimeiri said the algorithm provides physicians with a more functional view of HRD status by examining the transcriptome rather than the genome alone.

The announcement follows Tempus' recent non-exclusive distribution agreement with Median Technologies to expand AI-driven cancer diagnostics through the eyonis platform. Broader tech stocks also edged higher in the prior session, providing a supportive backdrop for the move.

Technical Analysis

Currently, the stock is trading 8.3% below its 20-day simple moving average (SMA) and 25.8% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased 35.86% over the past 12 months and are positioned closer to their 52-week lows than highs.

The RSI is at 35.53, which is considered neutral territory, while the MACD shows a value of -3.9401, below its signal line at -3.3917, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock’s near-term performance.

• Key Resistance: $61.50
• Key Support: $50.00

The launch of the HRD-RNA algorithm highlights Tempus’s commitment to leveraging AI in healthcare to enhance treatment options for patients. This innovative approach positions the company as a leader in precision medicine, potentially improving patient outcomes and expanding its market reach.

Earnings & Analyst Outlook

The countdown is on: Tempus AI is set to report earnings on February 24, 2026.

• EPS Estimate: Loss of 13 cents (Up from Loss of 18 cents YoY)
• Revenue Estimate: $364.25 million (Up from $200.68 million YoY)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $76.60. Recent analyst moves include:

• Baird: Initiated with Outperform (Target $59.00) (Feb. 17)
• Canaccord Genuity: Buy (Lowers Target to $80.00) (Dec. 22, 2025)
• JP Morgan: Neutral (Lowers Target to $80.00) (Dec. 15, 2025)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Weak (Score: 5.75) — Stock is underperforming the broader market.

The Verdict: Tempus AI’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the weak momentum score indicates underperformance, innovative developments in precision medicine could catalyze future growth.

Top ETF Exposure

• ARK Innovation ETF (NYSE:ARKK): 5.07% Weight
• ARK Genomic Revolution ETF (BATS:ARKG): 8.63% Weight

Significance: Because TEM carries significant weight in these funds, any significant inflows or outflows will likely trigger automatic buying or selling of the stock.

TEM Price Action: Tempus AI shares were up 3.41% at $54.35 during premarket trading on Wednesday, according to Benzinga Pro data.

Image: Shutterstock